HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 price target.
Why Is Plant-Based Medications-Focused ABVC BioPharma Stock Trading Higher Today?
ABVC BioPharma Inc (NASDAQ: ABVC) and its subsidiary BioLite Inc received an aggregate of 46 million shares from AiBtl BioPharma Inc as its first milestone payment under a global licensing agreement.